EF
BPMC

Empowered Funds’s Blueprint Medicines BPMC Stock Holding History

Empowered Funds’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-254
Closed -$22.2K – 1636
2024
Q4 		$22.2K Buy
+254
New +$23.3K ﹤0.01% 1639
2021
Q3 		– Sell
-48,044
Closed -$4.23M – 214
2021
Q2 		$4.23M Buy
+48,044
New +$4.4M 0.54% 46

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Empowered Funds's BPMC Position: Q1 2025 in Review

Empowered Funds sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 254 shares — an estimated $22.2K sold.

Empowered Funds first reported a position in BPMC in Q2 2021 and held it in 2 quarters. The position peaked at $4.23M in Q2 2021. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Empowered Funds reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Empowered Funds sold 254 Blueprint Medicines shares in Q1 2025, an estimated $22.2K.
  • Empowered Funds first reported a position in Blueprint Medicines in Q2 2021 and held it in 2 quarters.
  • Empowered Funds's Blueprint Medicines position peaked at $4.23M in Q2 2021.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Empowered Funds's 13F filing for Q1 2025, filed 16 May 2025.